![]() Financial Daily from THE HINDU group of publications Saturday, Feb 05, 2005 |
|
|
|
|
|
Corporate
-
Mergers & Acquisitions Phlox merger with Sun Pharma may have to wait for BIFR nod
Nithya Subramanian
New Delhi , Feb. 4 THE merger proposal of Phlox Pharmaceuticals with its parent company Sun Pharmaceuticals may have to be put on hold for a while. The ailing Phlox Pharmaceuticals is still awaiting the Board for Industrial and Financial Reconstruction nod. According to Sun Pharma officials, this Vadodara-based company would have to come out of the BIFR-fold before it can be merged with the parent. "We are seeking BIFR permission for the merger," said a company official. The company was registered with BIFR in 2003. As per the financial details, its net worth of Rs 23.61 crore was wiped out by accumulated losses of Rs 25.18 crore. Official sources said that the hearing is yet to be scheduled. Also, since the merger proposal of Phlox Pharma with the company is pending, the financial accounts for 2003-04 was not confirmed at the last annual general meeting. Phlox was set up by an expatriate and manufactured certain bulk actives with a workforce of about 60. Meanwhile, the board of directors of Sun Pharmaceuticals is expected to meet on February 8 to take up the issue of merging three other subsidiaries with it. These are investment companies - Bazley Finvest, Dhaval Finvest and Manish Finvest. Certain investments on fixed assets were made by these subsidiaries. Sun Pharma's market share in November 2003 stood at 3.27 per cent, up from 3.08 per cent recorded in the November before that. The company claims that its growth rate has been twice that of the industry rate of growth.
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|